HIV kq40

HIV kq40 Full Name

Human immunodeficiency virus 2 kq40

HIV kq40 Introduction

The HIV-2 envelope glycoprotein complex (Env) plays a central role in viral entry into host cells, with the transmembrane subunit HIV-2 gp39 envelope glycoprotein acting as the key mediator of membrane fusion. This protein is generated through cleavage of the gp160 precursor and is structurally and functionally analogous to HIV-1 gp41 envelope glycoprotein. It contains several critical domains, including the fusion peptide (FP), heptad repeat regions (HR1 and HR2), the membrane-proximal external region (MPER), and a transmembrane domain (TM). During viral entry, gp39 undergoes dramatic conformational changes, transitioning from a prefusion to a postfusion state. This process leads to the formation of a stable six-helix bundle, which brings the viral and cellular membranes into close proximity and ultimately enables membrane fusion. Due to its essential functional role, gp39 is not only critical for HIV-2 infectivity but also represents a major target for antiviral drugs and neutralizing antibodies.

In this context, "KQ40" has emerged as an important research tool associated with gp39. Rather than being a standard protein designation, KQ40 typically refers to a monoclonal antibody or a defined epitope that specifically recognizes gp39. Studies suggest that the epitope targeted by KQ40 is often located within functionally significant regions of gp39, such as the HR domains or the MPER, both of which are crucial for membrane fusion and antibody-mediated neutralization. The use of KQ40 enables precise mapping of antibody-binding sites, as well as detailed analysis of epitope exposure under different conformational states of gp39. Moreover, KQ40 has been employed to investigate differences in antibody recognition and immune sensitivity between HIV-1 and HIV-2, providing valuable insights into the relatively lower pathogenicity and distinct immunological characteristics of HIV-2.

From an application perspective, KQ40 holds significant potential in vaccine development, antibody screening, and diagnostic assay design. Because the epitopes it recognizes are often structurally conserved and functionally critical, they represent promising targets for immunogen design aimed at eliciting broadly neutralizing antibodies. In antibody discovery workflows, KQ40 can serve as a reference or benchmarking tool to evaluate binding affinity and neutralization potency of candidate antibodies. Additionally, KQ40-based immunoassays, such as ELISA or lateral flow assays, may enable specific detection of HIV-2, particularly in distinguishing it from HIV-1 infections. Overall, the relationship between KQ40 and gp39 exemplifies a classic "target–probe" system, providing a powerful framework for advancing our understanding of HIV-2 membrane fusion mechanisms and supporting the development of effective therapeutic and diagnostic strategies.

Alternate Names for HIV kq40

HIV-2 kq40; Human immunodeficiency virus 2 kq40; HIV; Human immunodeficiency virus; Lentivirus; kq40

• 1. Ahmad M., et al. Engineered Expression of Broadly Neutralizing Antibodies Against Human Immunodeficiency Virus. Annual Review of Virology. 2017;4(1):491-510.
  2. Apetroaei M., et al. The Phenomenon of Antiretroviral Drug Resistance in the Context of Human Immunodeficiency Virus Treatment: Dynamic and Ever Evolving Subject Matter. Biomedicines. 2024;12(4):915.
  3. Azzman N., et al. Pharmacological advances in anti-retroviral therapy for human immunodeficiency virus-1 infection: A comprehensive review. Reviews in Medical Virology. 2024;34(2).
  4. Chabria S., et al. Deep Sequencing of HIV: Clinical and Research Applications. Annual Review of Genomics and Human Genetics. 2014;15(1):295-325.